SABCS 2022 | ELEANOR: real-world study of extended adjuvant neratinib in HER2+/HR+ early breast cancer

Rupert Bartsch, MD, Comprehensive Cancer Center Vienna, Vienna, provides an overview of the prospective, observational Phase IV ELEANOR (NCT04388384) trial, designed to investigate real-world use of neratinib and its treatment management in patients in patients with HR-positive, HER2-overexpressing/amplified breast cancer stage I-III at high-risk for recurrence. Patients receive neratinib at a standard dose for one year following completion of neoadjuvant treatment with chemotherapy and HER2-directed agents including trastuzumab and pertuzumab. Primary endpoint is the rate of patient’s adherent to neratinib treatment. Secondary objectives include characterization of patients scheduled to receive neratinib, details on neratinib treatment, recurrences, safety, and health-related quality of life (HRQoL). This interview took place at the San Antonio Breast Cancer Symposium (SABCS) 2022 in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.